Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

5 Jun 2023

Abstract excerpt

Chimeric antigen receptor (CAR)-T cell therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with response rates of 63–84% and complete response observed in 43–54%. Common germline variants of the target antigen CD19 may elicit different responses to CAR-T cell therapy. The CD19 gene single nucleotide polymorphism rs2904880 encoding leucine or valine at amino acid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Virus-based gene therapy research

Source

Identifiers

PMID: 37297020
DOI: 10.3390/cancers15113058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell TherapyPMID 37297020Read ↗

Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell TherapySemantic proximity Read ↗

The CD19 CAR T hinge region influences avidity and cytotoxicity in CD19 SNP variants in B-cell LymphomaSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaSemantic proximity Read ↗

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read ↗

The pan-cancer analysis uncovers the prognostic and immunotherapeutic significance of CD19 as an immune marker in tumorSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical TrialsSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling <i>CD19</i> splicing and CART-19 therapy resistanceSemantic proximity Read ↗

Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapySemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance.Semantic proximity Read ↗

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.